| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Gary W Pace is Director at CRDF, with reported holdings spanning 3 companies. Gary W Pace's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $25.4M at current prices.
Our model assigns Gary W Pace a middling insider score of 66/100, based on 16 past trades. Over a 12-month horizon, 69.2% of those trades were profitable, with an average 12-month return of +9.0%.
Gary W Pace's largest disclosed position is in RMD as Director, worth about $22.8M. The RMD filings lean toward selling, a net 28,403 shares.
Gary W Pace has 40 Form 4 filings on record from March 2015 to July 2026, across 3 companies: Director at Cardiff Oncology (CRDF), 2020–2026; Director at Pacira BioSciences (PCRX), 2015–2024; Director at Resmed (RMD), 2018.
The 69 reported transactions were 23 open-market purchases, 17 option or other derivative awards, 12 option exercises and 9 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 16 purchases worth about $4.5M and 4 sales worth about $8.6M.
The largest open-market purchase was 687,285 shares of CRDF at an average $1.46 on July 14, 2026, about $1.0M.
The largest open-market sale was 119,323 shares of PCRX at an average $30.64 on March 8, 2024, about $3.7M. Twelve months later PCRX was down 26%.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 14, 2026 | CRDF Cardiff Oncology, Inc. | Director | Buy | 687,285 | $1.46 | $999,999.68 | +50.7% | -20.6% | - | |
| Jun 18, 2026 | CRDF Cardiff Oncology, Inc. | Director | Buy | 30,000 | $1.22 | $36,600.00 | +2.3% | +11.6% | - | |
| Jul 30, 2025 | CRDF Cardiff Oncology, Inc. | Director | Buy | 290,000 | $2.45 | $710,500.00 | +27.5% | -7.6% | - | |
| Dec 11, 2024 | CRDF Cardiff Oncology, Inc. | Director | Buy | 361,615 | $2.60 | $940,199.00 | +51.8% | -3.2% | -33.1% | |
| Mar 8, 2024 | PCRX Pacira Biosciences, Inc. | Director | Sell | 119,323 | $30.64 | $3,656,226.39 | -84.4% | -7.3% | -25.6% | |
| Dec 19, 2023 | CRDF Cardiff Oncology, Inc. | Director | Buy | 30,000 | $1.37 | $41,100.00 | +4.5% | +280.1% | +230.1% | |
| Nov 10, 2023 | CRDF Cardiff Oncology, Inc. | Director | Buy | 22,950 | $0.98 | $22,491.00 | +3.6% | +80.0% | +208.0% | |
| May 11, 2023 | PCRX Pacira Biosciences, Inc. | Director | Sale+OE | 5,015 | $41.78 | $209,526.70 | -3.5% | -9.4% | -30.0% | |
| Sep 15, 2022 | CRDF Cardiff Oncology, Inc. | Director | Buy | 150,000 | $1.71 | $256,500.00 | +30.3% | -15.6% | +3.6% | |
| Mar 1, 2022 | PCRX Pacira Biosciences, Inc. | Director | Sale+OE | 30,000 | $66.87 | $2,006,150.28 | -18.8% | -6.5% | -35.9% |